Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.

摘要: Recurrent genetic abnormalities confer distinct morphologic features and play a role in determining the clinical behavior, prognosis adequate treatment of acute leukemia. In MENA region, only one study targets frequency modifications AML, reporting higher occurrence promyelocytic leukemia Lebanon. Determining translocations gene mutations myeloid lymphoid cases an adult patients’ population Lebanon comparing resultant profile with published international molecular Laboratory results patients diagnosed AML or ALL presenting to AUBMC for profiling between years 2006 until June 2016 were reviewed. Genetic our CAP accredited diagnostics laboratory consists validated lab developed RT-PCR detection RUNX1/RUNX1T1, CBFB/MYH11, KMT2A/MLLT3, PML-RARA, BCR-ABL FLT3 receptor, NPM1, c-kit CEPBA genes. The panel tests presence BCR-ABL1, ETV6/RUNX1; KMT2A/AFF1, TCF3-PBX1. We reviewed 580 175 cases. cohort, M:F ratio was 1.3:1 mean age 50 years. t(15;17) present 7.6%, t(8;21) 4.2%, inv(16) 3.7%, t(9;22) 2.2% t(9;11) 1.7% mutation (ITD TKD) 25.2% all 30.1% Cytogenetics-normal (CN) patients. Mutations NPM1 31.4% 43.8% CN Double positive (NPM1+/FLT3+) accounted 20% NK CEBPA detected 7.3% 2.4% respectively. 37 years. B- T-lymphoblastic constituted 84.6% 15.4% 1.2:1 2.86:1 B-ALL 14.2%, t(4;11) 5.4%, t(1;19) 2.7% t(12;21) 1.4%. T-ALL negative found panel. A lower leukemic Lebanese as compared Western Other interesting findings percentage inv(16), incidence TCF3-PBX1, mild increase Philadelphia positivity cohort. less than expected lymphoblastic Full by next generation sequencing is required further classification into prognostic categories. This will be baseline reference future research epidemiological data useful transplant centers oncologists both region.